Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.92 USD
Change Today -0.06 / -3.03%
Volume 204.0K
PLX On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
Tel Aviv
As of 8:04 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

protalix biotherapeutics inc (PLX) Snapshot

Open
$1.95
Previous Close
$1.98
Day High
$1.97
Day Low
$1.88
52 Week High
06/30/14 - $3.78
52 Week Low
03/13/15 - $1.53
Market Cap
179.5M
Average Volume 10 Days
113.5K
EPS TTM
$-0.30
Shares Outstanding
93.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTALIX BIOTHERAPEUTICS INC (PLX)

protalix biotherapeutics inc (PLX) Related Businessweek News

No Related Businessweek News Found

protalix biotherapeutics inc (PLX) Details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-106, an oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and PRX-112, an orally administered glucocerebrosidase enzyme (GCD) for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD produced and encapsulated within carrot cells. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

234 Employees
Last Reported Date: 03/12/15
Founded in 1993

protalix biotherapeutics inc (PLX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $93.7K
Founder and Executive Vice President of Resea...
Total Annual Compensation: $395.5K
Chief Financial Officer, Vice President, Secr...
Total Annual Compensation: $524.1K
Chief Operating Officer
Total Annual Compensation: $283.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.9K
Compensation as of Fiscal Year 2014.

protalix biotherapeutics inc (PLX) Key Developments

Protalix BioTherapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 01:00 PM

Protalix BioTherapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 01:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Moshe Manor, Chief Executive Officer, President and Director.

Protalix BioTherapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Protalix BioTherapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $4,392,000 against $6,696,000 a year ago. Operating loss was $4,843,000 against $6,468,000 a year ago. Net loss for the period was $5,972,000 against $7,345,000 a year ago. Net loss per share of common stock - basic and diluted was $0.06 against $0.08 a year ago.

Protalix BioTherapeutics, Inc. Presents at UBS Global Healthcare Conference, May-20-2015 10:30 AM

Protalix BioTherapeutics, Inc. Presents at UBS Global Healthcare Conference, May-20-2015 10:30 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Moshe Manor, Chief Executive Officer, President and Director, Yossi Maimon, Chief Financial Officer, Vice President, Secretary and Treasurer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLX:US $1.92 USD -0.06

PLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLX.
View Industry Companies
 

Industry Analysis

PLX

Industry Average

Valuation PLX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTALIX BIOTHERAPEUTICS INC, please visit www.protalix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.